NJ Bio and Ajinomoto Bio-Pharma Services partner to advance ADC and AOC development

CAR-T Digest - August 2020

31 March 2026: NJ Bio and Ajinomoto Bio-Pharma Services partner to advance ADC and AOC development

NJ Bio and Ajinomoto Bio-Pharma Services have entered into a research collaboration to expand access to AJICAP™, a site-specific conjugation platform supporting ADC and antibody-oligonucleotide conjugate development
Under the agreement, NJ Bio will integrate the AJICAP™ platform into its drug discovery and early development workflows, enabling broader access to advanced conjugation technologies
This collaboration focuses on addressing key challenges in ADC development, particularly the need for more precise and reproducible conjugation methods to improve drug stability and safety
AJICAP™ is a site-specific conjugation platform that allows precise attachment of payloads to antibodies without the need for antibody engineering, helping maintain antibody function and improve pharmacokinetics
By combining NJ Bio’s expertise in bioconjugation with AJICAP™ technology, the collaboration is expected to enhance ADC design, reduce development risk, and improve overall therapeutic potential